Figure_3.tif (562.38 kB)
Comparison of hEBV321 and Bevacizumab binding properties to human VEGF.
figure
posted on 2013-02-21, 02:50 authored by Yanlan Yu, Pierre Lee, Yaohuang Ke, Yongke Zhang, Qiu Yu, Jonathan Lee, Mingzhen Li, Jialiang Song, Jungang Chen, Jihong Dai, Fernando Jose Rebelo Do Couto, Zhiqiang An, Weimin Zhu, Guo-Liang YuA. VEGF competition ELISA measuring the binding of hEBV321 to VEGF coated on ELISA plate in the presence of increasing concentration of competitor (hEBV321, Bevacizumab or an irrelevant antibody Humira). B-E. Direct binding of hEBV321 and Bevacizumab to various forms of human VEGF captured on ELISA plate. B. VEGF wild type; C. VEGF I46A; D. VEGF G89A; E. VEGF G88A/Q89A.
